Phase II Single-Arm Trial of Cladribine and Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Older Patients with Acute Myeloid Leukemia

BACKGROUND: Frontline therapy for older and/or unfit patients with acute myeloid leukemia (AML) remains unsatisfactory. We studied a new lower-intensity regimen of cladribine combined with low-dose cytarabine (LDAC) alternating with decitabine (DAC) aimed to improve outcomes in this population Based...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Kadia, Tapan M., Cortes, Jorge, Ravandi, Farhad, Jabbour, Elias, Konopleva, Marina, Benton, Christopher B., Burger, Jan, Borthakur, Gautam, DiNardo, Courtney D., Pemmaraju, Naveen, Daver, Naval, Ferrajoli, Alessandra, Wang, Xuemei, Patel, Keyur, Jorgensen, Jeffrey L., Wang, Sa, O’Brien, Susan, Pierce, Sherry, Tuttle, Carla, Estrov, Zeev, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775639/
https://ncbi.nlm.nih.gov/pubmed/30115541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30132-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados